With the upcoming release of Wingspan eTMF 2.0, Wingspan Technology is holding an exclusive preview webinar
With the upcoming release of Wingspan eTMF 2.0, Wingspan Technology is holding an exclusive preview webinar
January 13, 2014; BLUE BELL, PA— Wingspan Technology, Inc. plans to release its Wingspan eTMF overhaul, eTMF 2.0 in Q1 2014. On January 22, 2014, Wingspan will debut its revolutionary eTMF product for the first time for public demonstration.
While many document management system interfaces have remained largely unchanged since the 1990s, Wingspan eTMF 2.0 has been re-designed to provide:
· A user experience modeled on commercial web sites such as Amazon and eBay – dramatically reducing user training time and frustration
· Unprecedented insight into the status and health of ongoing trials
· Simple processes for uploading and checking documents that greatly decrease both the time needed for these processes and the possibility of error
Behind the scenes, Wingspan eTMF 2.0 uses the robust and scalable infrastructure and processes that have a proven track record of supporting users in more than 60 countries worldwide in processing up to 10,000 documents per day. Registration for this demo is currently open; you can register online here.
About Wingspan Technology, Inc.
Wingspan Technology, Inc. is the leading provider of life sciences and eClinical software solutions, including Wingspan eTMF and DocWay, the SharePoint/Documentum integration product suite. Wingspan's talented and knowledgeable engineering and project management teams offer in-depth industry knowledge and experience to companies in life sciences, pharmaceutical, financial services, and other fields.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.